Press release
Investigation announced for Long-Term Investors in Cidara Therapeutics, Inc. (NASDAQ: CDTX) over potential Wrongdoing
An investigation on behalf of investors in Cidara Therapeutics, Inc. (NASDAQ: CDTX) shares over potential wrongdoing.
Investors who purchased shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Cidara Therapeutics, Inc. (directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. Cidara Therapeutics, Inc. reported that its annual Total Revenue declined form $64.44 million in 2022 to $63.9 million in 2023, and that its Net Loss declined from $33.58 million in 2022 to $24.48 million in 2023.
On April 16, 2024, Cidara Therapeutics, Inc. filed a current report on Form 8-K with the SEC. In this 8-K, Cidara Therapeutics announced that it's "previously issued audited consolidated financial statements for the fiscal years ended December 31, 2021 and 2022 included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and each of the Company's previously issued unaudited condensed consolidated financial statements included in the Company's Quarterly Reports on Form 10-Q for each of the quarterly periods in 2022 and 2023 (collectively, the "Prior Financial Statements") filed with the [SEC] should no longer be relied upon and should be restated[.]"
Shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) declined from $29.60 per share on May 23, 2023, to as low as $10.00 per share on April 22, 2024.
Those who purchased shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in Cidara Therapeutics, Inc. (NASDAQ: CDTX) over potential Wrongdoing here
News-ID: 3535084 • Views: …
More Releases from Shareholders Foundation
Lawsuit filed for Investors who lost money with shares of Spirit Aviation Holdin …
An investor, who purchased shares of Spirit Aviation Holdings, Inc. (OTC: FLYYQ), filed a lawsuit over alleged violations of Federal Securities Laws by Spirit Aviation Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Spirit Aviation Holdings, Inc. (OTC: FLYYQ) between May 28, 2025 and August 29, 2025, have certain options and for certain investors are short and strict deadlines…
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
More Releases for Cidara
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
The influenza A market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM influenza A market size from 2020 to 2034. The report also covers current influenza A treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are…
Seasonal Influenza Market to Reach New Heights in Growth by 2034, DelveInsight P …
The Key Seasonal Influenza Companies in the market include - Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Novavax, Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis, and others.
DelveInsight's "Seasonal Influenza Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know…
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.
DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,…
Influenza A Infections Market Overview: Size, Share, and Future Growth 2024 - 20 …
According to a new report published by CoherentMI The influenza A infections market is estimated to be valued at USD 723.2 Mn in 2024 and is expected to reach USD 873.4 Mn by 2031, growing at a compound annual growth rate (CAGR) of 2.7% from 2024 to 2031
Most recent Report, named "Influenza A Infections Market" Patterns, Offer, Size, Development, Opportunity and Forecast 2024-2031, by CoherentMI offers a complete investigation…
Candidiasis Therapeutics Market Growing Rapidly by 2031- Cidara Therapeutics Inc …
DataM Intelligence has published a new research report on "Candidiasis Therapeutics Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF -…
Candidemia Market Forecast by 2032: Epidemiology Analysis, Emerging Therapies, R …
The Candidemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Candidemia pipeline products will significantly revolutionize the Candidemia market dynamics.
DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
